Immune checkpoint inhibitors have revolutionized cancer treatment, yet many colorectal tumors remain resistant. Even among ...
IBC comprises ~1%–5% of U.S. breast cancers and typically lacks a palpable lump, with dermal lymphatic blockage driving diffuse swelling, erythema, and rapid progression over weeks to months. Failure ...